Emerging Highlights of Antibody Therapy in Oncology

Chen D

Research Institute of Biological Medicine, Yiling Pharmaceutical, China

^*Correspondance to: Daohong Chen 

 PDF  Full Text Short Communication | Open Access

Abstract:

As a hallmark of biological medicine, monoclonal antibody (mAb) therapy has evolved into the mainstream treatment in clinical oncology at a relatively fast pace. Whereas a therapeutic mAb was traditionally designed to block signaling molecules driving malignant cell growth or tumor angiogenesis, mAb-based agents are currently explored further in comprehensive contexts of disease biology, including immune checkpoint blockade, antibody-drug conjugates, Fc region modification, bispecific antibody, among others. Herein, this article outlines an updated understanding of these emerging avenues derived from mAb platforms, which are coming up with better innovative medicines to fight cancer.

Keywords:

Cite the Article:

Chen D. Emerging Highlights of Antibody Therapy in Oncology. Clin Oncol. 2016; 1: 1026.